Clinical Trials in the UK / NCT05062291
Active, not recruiting
Observational
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Venous StenosisVenous Occlusion
Investigational drug(s) / intervention(s)
Merit WRAPSODY Endovascular Stent Graft
Merit WRAPSODY Endovascular Stent Graft: Target Lesion Primary Patency (TLPP)
Study summary
The WRAP Study aims to expand and understand the safety and efficacy data on the WRAPSODY Endoprosthesis System in a real-world population.
Eligibility
Inclusion Criteria:
1. Subject provides written informed consent for study participation.
2. Subject is male or female, with an age ≥ 18 years at date of enrollment.
3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 24 months.
4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon
5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.
6. Subject has stenosis or occlusion within the dialysis outflow circuit of an arteriovenous (AV) fistula or AV graft and is treated with WRAPSODY Endoprosthesis System in accordance with device instructions for use.
Exclusion Criteria:
1. Subject has a planned surgical revision of access site.
2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia.
3. Subject has an uncorrectable coagulation disorder.
4. Known hypersensitivity to nickel titanium alloy.
5. Subject's hemodialysis access is anticipated to be abandoned within 6 months.
6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.
7. Full expansion of a Percutaneous Transluminal Angioplasty (PTA) balloon cannot be achieved during predilatation.
8. Device would be placed in the Superior Vena Cava
9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.
Primary outcome measure(s)
- Proportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) — 6 months
Proportion of subjects with Target Lesion Primary Patency (TLPP) at 6 Months. TLPP is defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or target lesion thrombosis measured through 6 months post-procedure, which is the time interval of uninterrupted patency after study procedure to the next intervention performed on the target lesion or uncorrectable target lesion occlusion. - Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint) — 30 days
Proportion of subjects without any localized or systemic safety events through 30 days post-index procedure that affect the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including stenosis or thrombosis).
Trial sites (35)
| Facility | City | Region | Status |
|---|---|---|---|
| Monash Health | Clayton | Australia | |
| Liverpool Hospital | Liverpool | Australia | |
| Fiona Stanley Hospital | Murdoch | Australia | |
| Sir Charles Gairdner Hospital | Nedlands | Australia | |
| Princess Alexandra Hospital | Woolloongabba | Australia | |
| Hospital Felicio Rocho | Belo Horizonte | Brazil | |
| Afya Hospital | Brasília | Brazil | |
| Hospital Santa Lucia | Brasília | Brazil | |
| Hospital Vera Cruz | Campinas | Brazil | |
| Instituto Pro Renal | Curitiba | Brazil | |
| Complexo Hospitalar de Niterói | Niterói | Brazil | |
| Parana Medical Research Center | Paranã | Brazil | |
| Real Hospital Português de Beneficência em Pernambuco | Recife | Brazil | |
| Impar Servicos Hospitalares S/A - Hospital Sao Lucas | Rio de Janeiro | Brazil | |
| Rio de Janeiro State University | Rio de Janeiro | Brazil | |
| Hospital Da Bahia | Salvador | Brazil | |
| Centro Internacional de Pesquisa do Hospital Alemão Oswaldo Cruz | São Paulo | Brazil | |
| Hospital Santa Rita de Cassia | São Paulo | Brazil | |
| Instituto Dante Pazzanese de Cardiologia | São Paulo | Brazil | |
| Protestant Hospital Queen Elisabeth Herzberge | Berlin | Germany | |
| University of Cologne | Cologne | Germany | |
| The General University Hospital of Patras | Rio | Greece | |
| Shaare Zedek Medical Center | Jerusalem | Israel | |
| Maastricht UMC+ | Maastricht | Netherlands | |
| Te Toka Tumai Auckland | Auckland | New Zealand | |
| Te Whatu Ora Health NZ Waitemata | Auckland | New Zealand | |
| Te Whatu Ora Health NZ Waitaha Canterbury | Christchurch | New Zealand | |
| Te Whatu Ora Health New Zealand Waitemata | Hamilton | New Zealand | |
| CHUC - Centro Hospitalar e Universitário De Coimbra | Coimbra | Portugal | |
| Belfast City Hospital, Belfast Health and Social Care Trust | Belfast | United Kingdom | |
| Queen Elizabeth Hospital, University Hospital Birmingham | Birmingham | United Kingdom | |
| King's College Hospital, NHS Foundation Trust | London | United Kingdom | |
| Royal London Hospital, Barts Health NHS Trust | London | United Kingdom | |
| Churchill Hospital, Oxford University Hospitals NHS Foundation Trust | Oxford | United Kingdom | |
| Royal Berkshire NHS Foundation Trust | Reading | United Kingdom |
More Merit Medical Systems, Inc. trials in the UK
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05062291 on ClinicalTrials.gov ↗ ← All trials in the UK